p**g
发帖数: 4595 | 1 Why drugs fall short in late-stage trials
Pharma companies should learn to segment the drugs in their pipelines by
risk.
Maria A. Gordian, Navjot Singh, and Rodney W. Zemmel
Web exclusive, November 2006
The third and final stage of clinical testing is designed to confirm the
efficacy and safety of new drugs under development. Yet McKinsey research
finds that, surprisingly, as many as four drugs in ten fail during this
phase. To reduce the high number of late failures, pharmaceutical companies
sh | K******S
发帖数: 10109 | 2 "some drugmakers reward senior managers for the number of products in the
pipeline at one stage or another and not necessarily for making good
decisions about them."
ft.
companies
【在 p**g 的大作中提到】
: Why drugs fall short in late-stage trials
: Pharma companies should learn to segment the drugs in their pipelines by
: risk.
: Maria A. Gordian, Navjot Singh, and Rodney W. Zemmel
: Web exclusive, November 2006
: The third and final stage of clinical testing is designed to confirm the
: efficacy and safety of new drugs under development. Yet McKinsey research
: finds that, surprisingly, as many as four drugs in ten fail during this
: phase. To reduce the high number of late failures, pharmaceutical companies
: sh
|
|
